Skip to content
Back to meeting Original
ESMO Open· @ESMO_Open · X·· 2 days agoScore70

tucatinib

Body

Addition of Tucatinib to Trastuzumab/Pertuzumab After Local Therapy for Isolated icPD in HER2+mBC: Primary Results of the Ph2 BRIDGET Trial in @ESMO_Open presented at #ESMO2026. Median icPFS not reached (mFUP 19.6 months), 46/47 pts alive @ data cut-off. https://www.esmoopen.com/article/S2059-7029(26)02587-1/fulltext

19 views · 0 likes · 0 reposts · 0 replies

Conference abstracts
1766ROmatched by Rapid oral 1: Breast cancer, advanced stage

Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC

https://esmocongress.esmo.org

Source: ESMO Open · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.